Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyMHN proton and neutron beam coverage | OpenPayer
    Ask Trek AI about this page
    CurrentmhnPolicy CP.MP.70

    Proton and Neutron Beam Therapies

    Customize your policy alerts

    Sign up for mhn Policy CP.MP.70 alerts

    Get alerted when Policy CP.MP.70 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and guidance for coverage of proton beam therapy (PBT) and neutron beam therapy (NBT) for members/enrollees of Centene-affiliated health plans; intended for clinicians and prior authorization reviewers.

    Policy Summary
    Payermhn
    PolicyProton and Neutron Beam Therapies
    Policy CodePolicy CP.MP.70
    Change TypeNo material changes noted
    Effective Date
    Last ReviewNov 25, 2025
    Next Review Date
    Key ActionObtain prior authorization for PBT/NBT and document that the requested indication meets the listed medically necessary criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~23distinct PBT indications enumerated
    salivary glandexplicit NBT coverage indication
    ≤21age-specific covered indication
    N/Adefault non-covered uses
    6 codesprocedure codes referenced
    2014-2025revision history entries

    Coverage Criteria for Proton and Neutron Beam Therapies

    inv-02: NBT medical necessity indications

    Neutron beam therapy (NBT) is medically necessary for salivary gland tumors when ANY of the following are met:

    NBT covered indications: A. The tumor is considered surgically unresectable, recurrent, or is resected with gross residual disease or positive margins; B. Member/enrollee is medically inoperable.

    NBT coverage limited to these salivary gland tumor scenarios.

    inv-03: Policy criteria and historical additions

    Policy includes a comprehensive set of criteria (I.A through I.W and II) for indications where proton and/or neutron therapy may be considered medically necessary; numerous additions and refinements were made across annual reviews.

    policy_criteria_changes_overview: Over multiple annual reviews the policy expanded and refined covered indications to include specific CNS tumors (benign and malignant primary CNS tumors excluding IDH wild-type GBM), inclusion of intraocular melanomas, clarification of spine/spinal cord indications, addition of pituitary neoplasms, expansion of pediatric age threshold to ≤ 21 years, inclusion of tumors in members with cancer-predisposing genetic mutations, addition of mediastinal tumors (including thymomas/thymic carcinoma), malignant pleural mesothelioma, primary bone tumors, medically inoperable surgical cancers requiring dose escalation, craniospinal irradiation indications, esophageal cancers, advanced unresectable pelvic tumors, single or transplanted kidney scenarios requiring organ avoidance, salivary gland tumors, and arteriovenous malformations (AVM).

    This node summarizes revisions to criteria across documented annual reviews and clarifications.

    inv-04: Neutron Beam Therapy clinical stance

    Clinical stance regarding Neutron Beam Therapy (NBT).

    NBT_stance: NBT has limited adoption and availability; it has been most commonly studied for salivary gland tumors that are unresectable or recurrent. NCCN historically considered NBT promising for unresectable salivary gland cancer but no longer recommends it as a general solution due to diminishing demand, high rates of long-term toxicity, concerns about the methodological robustness of randomized trial data, and closure of most U.S. centers; however, the panel recognizes potential clinical value for select patients.

    Derived from NCCN position and clinical context.

    All other indications for proton beam therapy (PBT) and neutron beam therapy (NBT) that are not explicitly listed in this policy are considered not medically necessary. The policy states that insufficient evidence exists to recommend PBT and/or NBT as superior to other available treatments outside of the enumerated indications, and such requests would be denied when not meeting the specific covered criteria.

    The NCCN commentary referenced in this policy indicates that neutron beam therapy (NBT) was historically considered promising for unresectable salivary gland cancers but is no longer recommended as a general solution. Reasons cited include diminishing demand, high rates of long-term toxicity, concerns about the methodological robustness of randomized trial data, and the closure of nearly all U.S. treatment centers; NCCN acknowledges NBT may still have potential value for select patients.

    Any request for PBT or NBT that does not meet one of the policy’s enumerated indications is considered not medically necessary. Approval is limited to the specific clinical scenarios listed in the policy; uses outside those scenarios should be treated as non-covered absent additional supporting evidence.

    Inclusion of CPT codes or other procedure codes in this clinical policy is for informational purposes only and does not guarantee coverage. The absence of explicit coverage language for a particular clinical presentation in this excerpt should not be interpreted as medical necessity; providers must verify plan-specific coding and coverage guidance prior to claim submission.

    Procedure and Billing Codes

    Referenced CPT codingCPT
    CPT referenced (no specific codes listed in this part)Policy references CPT codes and descriptions for informational purposes; no explicit CPT codes provided in this document section.
    Referenced Procedure CodesCPT
    77423High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s).
    77520Proton treatment delivery; simple, without compensation.
    77522Proton treatment delivery; simple, with compensation.
    77523Proton treatment delivery; intermediate.
    77525Proton treatment delivery; complex.
    S8030Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy.
    Age threshold — pediatric/young adult
    Age thresholdMembers/enrollees ≤21 years for primary or benign solid tumors or other hematologic malignancies
    ApplicabilityApplies to pediatric and young adult members when listed tumor types meet other policy criteria
    Evidence basisPolicy updated age cutpoint from ≤18 to ≤21 years in revisions (see document history)

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for requests for proton beam therapy (PBT) and neutron beam therapy (NBT). Approval is limited to the medically necessary indications listed in this policy. Providers should follow Health Plan procedures to obtain prior authorization and verify any plan‑specific requirements before scheduling treatment.

    • Prior authorization required for PBT and NBT for covered indications only
    • Approval limited to listed medically necessary indications; requests for other indications are likely to be denied
    Note

    Preference for Photon Therapy When Constraints Met

    Photon (x‑ray) therapy is the preferred modality when normal tissue and organ‑at‑risk dose constraints can be met. Proton therapy should be reserved for cases in which photon‑based techniques would exceed organ‑at‑risk constraints or where a proton‑based technique lowers the probability of clinically meaningful normal tissue toxicity.

    • Photon therapy preferred when normal tissue constraints can be satisfied

    Background and Rationale

    Proton beam therapy (PBT) is an external beam radiation modality that uses protons to deliver dose with a distinct depth-dose profile, characterized by limited exit dose beyond the target. This physical property allows for greater sparing of surrounding normal tissues and critical structures compared with conventional photon therapy, which can be particularly beneficial for well-demarcated tumors, pediatric patients, and situations where photon-based approaches cannot meet organ-at-risk constraints. PBT is therefore used clinically when its depth-dose characteristics enable dose escalation or organ preservation that would not be achievable with photons.

    Definitions

    Proton beam therapy (PBT) — definition & summary
    DefinitionProton beam therapy (PBT) is an external beam radiation therapy using protons to precisely target tissue with a distinct depth–dose profile that reduces dose to surrounding normal tissues.
    Key characteristicDelivers dose with limited exit dose, sparing surrounding normal tissue and useful for well‑demarcated tumors and cases where critical structure dose constraints are a concern.
    Typical indicationsOften used for ocular tumors, pediatric tumors, skull base/spinal tumors, re‑irradiation, and other indications where photon constraints cannot be met.
    Neutron beam therapy (NBT) — definition & historical context
    DefinitionNeutron beam therapy (NBT) is an external beam radiation modality that utilizes neutrons, rather than photons, to destroy tumor cells.
    Clinical context
    Policy Summary
    Payermhn
    PolicyProton and Neutron Beam Therapies
    Policy CodePolicy CP.MP.70
    Change TypeNo material changes noted
    Effective Date
    Last ReviewNov 25, 2025
    Next Review Date
    Key ActionObtain prior authorization for PBT/NBT and document that the requested indication meets the listed medically necessary criteria.
    SourceLink
    On This Page
    Coverage Criteria for Proton and Neutron Beam TherapiesProcedure and Billing CodesProvider Requirements and AuthorizationBackground and RationaleDefinitions
  1. PBT indicated when photon therapy would exceed critical organ dose constraints
  2. Documentation Required

    Required Clinical and Coding Documentation

    Providers must submit clinical documentation to support the medical necessity of PBT/NBT. Required documentation includes tumor localization and treatment‑planning information (for example: imaging reports such as MRI/CT, operative reports, pathology, documentation of fiducial placement when applicable, and radiation treatment planning details demonstrating organ‑at‑risk doses and comparisons to photon plans).

    • Imaging and tumor localization (MRI, CT, ultrasound, ophthalmoscopy where applicable)
    • Operative and pathology reports when relevant
    • Documentation of fiducials or localization technique for ocular tumors
    • Radiation treatment planning details, including organ‑at‑risk dose constraints and comparison to photon plans
    Step Therapy

    Step Therapy

    In some instances, step therapy may be relevant when alternative, clinically appropriate radiation modalities exist; however, this policy does not specify explicit step therapy requirements. Providers should confirm any plan‑level step therapy or utilization management protocols that may apply.

    • No explicit step therapy requirements specified in this policy
    • Verify plan‑specific step therapy or utilization management rules
    Billing Rule

    Coding Does Not Guarantee Coverage

    Inclusion of procedure or diagnosis codes in this policy is for informational purposes only and does not guarantee coverage. Providers must reference the most current coding guidance and verify benefit, coverage, and claim submission requirements with the member's Health Plan prior to billing.

    • Coding references are informational only; inclusion or exclusion does not ensure coverage
    • Verify up‑to‑date coding guidance and plan benefit coverage before claim submission
    Neutrons are heavier than photons and may be more effective against very dense tumors; clinical use has been limited due to delivery difficulties and availability constraints.
    Historical focusMost commonly studied historically for unresectable or recurrent salivary gland tumors.
    Neutron Beam Therapy (NBT) — characteristics & limitations
    Mechanism & limitationsNBT uses neutrons which can cause greater damage to dense tumors but is technically difficult to generate and deliver, limiting adoption and availability.
    Toxicity and evidence concernsNCCN no longer recommends NBT as a general solution for salivary gland cancers due to high long‑term toxicity, limited robust randomized trial data, and closure of most U.S. centers; it may be considered for select patients.
    Current availabilityClinical adoption is limited; only a small number of centers historically offered NBT, contributing to its reduced use in contemporary practice.